The Missing Lynx

Premium

Lynx Therapeutics is misnamed, low on funds, and short on marketing talent. But if it can overcome all that, it has one hell of a product to sell you

 

By Aaron J. Sender

 

“One of the most fulfilling things in this job,” says Lynx Therapeutics CEO Norrie Russell, whose role is to enlighten outsiders about his company’s product, “is when they stop being glassy-eyed and say, ‘Holy shit! I’ve got it.’”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.

Bloomberg profiles IndieBio, a startup incubator for the life sciences.

In an editorial, Nature calls for the end to the exploitation of foreign postdocs.

In Nucleic Acids Research this week: collection of epigenome-wide association study data, updated BloodSpot database, and more.